Acetyl Glu 1 + GIP (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) are two incretin hormones that play significant roles in regulating glucose metabolism and have therapeutic potential for improving insulin sensitivity and promoting weight loss. Research and studies, especially those involving drugs like tirzepatide that combine GIP and GLP-1 receptor agonism, highlight several key benefits:

Improved Blood Sugar Control: Both GLP-1 and GIP influence insulin secretion in response to meals. GLP-1 enhances insulin release when glucose levels are elevated and also inhibits glucagon release, reducing hepatic glucose production. Combined with GIP's effects, which amplify insulin secretion, this dual-action helps better regulate blood sugar levels, especially beneficial in type 2 diabetes​

Weight Loss: GLP-1 agonists are widely recognized for their ability to support weight reduction. They achieve this through mechanisms such as reducing appetite and slowing gastric emptying. When paired with GIP, which has complementary effects on metabolism, the combination can further enhance these outcomes, leading to more significant weight loss compared to GLP-1 agonists alone​

Cardiovascular Benefits: Clinical studies have shown that GIP and GLP-1 receptor agonists can have cardiovascular benefits, including lowering the risk of major adverse cardiovascular events. Tirzepatide, for instance, has shown to significantly reduce blood sugar and body weight while also providing cardiovascular protection​

Improved Insulin Sensitivity: The combination of GIP and GLP-1 receptor activation may help improve insulin sensitivity in peripheral tissues, which is crucial for managing type 2 diabetes and prediabetes​

Read Less

Side effects of using Acetyl Glu 1 + GIP, like other GLP-1 and GIP receptor agonists, can occur, though their intensity and frequency may vary depending on the specific medication and the individual's response. Below are some potential side effects reported in scientific studies:

Gastrointestinal Issues:
GLP-1 agonists, such as tirzepatide (which targets both GLP-1 and GIP receptors), may cause gastrointestinal side effects. The most commonly reported symptoms include:
nausea,
vomiting,
stomach pain,
diarrhea,
constipation​

Read Less

This chemical reagent is specifically designed for High-Performance Liquid Chromatography (HPLC) testing and analysis. It is a high-purity compound intended for laboratory use only and is not suitable for human consumption, ingestion, or medical use. The reagent is used for separating, identifying, and quantifying chemical substances in various samples, meeting the stringent quality and purity standards necessary for precise and reliable HPLC analysis. By purchasing this product, the buyer acknowledges and accepts the manufacturer’s guidelines and handling instructions to ensure safety and optimal performance.

Intended Use:

• For use in HPLC testing and analysis in laboratory environments.
• Ideal for separating and quantifying chemical components in various matrices.
• Not intended for human, animal, or pharmaceutical use.

Important Notes:

• This product is strictly intended for research and industrial applications.
• The buyer must adhere to the manufacturer’s instructions for use, handling, and storage.
• The manufacturer is not responsible for any damage or adverse outcomes resulting from the failure to follow these instructions.
• Proper safety equipment (gloves, goggles, etc.) should be worn during handling.
• Dispose of the product according to local regulations after use.

Read Less